Clinical Trial Update: A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Onartuzumab (MetMAb) plus paclitaxel and platinum versus placebo in squamous non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Onartuzumab (MetMAb) (onartuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED